1. Home
  2. Documents

Network for the Evaluation of Vaccine Effectiveness in Latin America and the Caribbean - influenza (REVELAC-i) Documents

Show filters
CIM-revelac-fluvax-averted-illness-pub2025-en.jpg
Influenza Vaccine-Averted Illness in Chile, Guyana, and Paraguay During 2013–2018: A Standardized Approach to Assess the Value of Vaccination
Other publications
Technical note on the SARInet and REVELAC-i networks
Technical note on the SARInet and REVELAC-i networks
Technical reports
CIM-revelac-mmwr-03oct2024-thumb
Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization — REVELAC-i Network, Five South American Countries, March–July 2024
Technical bulletins
im-revelac-effectiveness-of-covid-19_vaccines-2023-en.jpg
Effectiveness of COVID-19 vaccines against hospitalisation in Latin America during three pandemic waves, 2021–2022: a test-negative case-control design
Technical and scientific products
im-revelac-ve-covid-19-2021-22-pry-en
COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021—April 2022: A test negative design
Technical and scientific products
IM-revelac-End-of-season-flu vaccine-chl-pry-ury-2022-en
End-of-season influenza vaccine effectiveness during the Southern Hemisphere 2022 influenza season –Chile, Paraguay, and Uruguay
Technical and scientific products
IM-revelac-mmwr-flu-vaccine-effectiveness-chile2022-en
Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022
Technical and scientific products
IM-Severity of influenza illness by seasonal influenza vaccination status-en
Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013–19: a surveillance-based cohort study
Technical and scientific products
WHO-2019-nCoV-vaccine-effectiveness-VE-evaluations-2022.1-eng.pdf.jpg
Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination: interim guidance, 1 October 2022: second addendum to Evaluation of COVID-19 vaccine effectiveness: interim guidance
Technical and scientific products
Evaluacion_efectividad_vacunacion_COVID_Chile_2021_SE28_2022.pdf
Evaluación de la efectividad de la vacuna contra la COVID-19 en Chile, 2021
Technical reports
REVELAC-COVID-19 Generic Protocol
Technical and scientific products
im-covid-vacc-effectiveness-adddendum-e
Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants: Interim guidance, 22 July 2021.
Technical and scientific products
IM-covid-vacc-effectiveness-e
Evaluation of COVID-19 vaccine effectiveness. Interim Guidance 17 March 2021
Technical and scientific products
Evaluation ofinfluenza vaccine effectiveness - A guide to the design and interpretation ofobservational studies
Evaluation of influenza vaccine effectiveness - A guide to the design and interpretation ofobservational studies
Technical and scientific products
Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits
Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits
Technical and scientific products
Multicenter Evaluation of the Effectiveness of Seasonal Influenza
Guidelines
Operational Guidelines for Sentinel Severe Acute Respiratory Infection (SARI) Surveillance; 2014
Guidelines
Presentation - Influenza Vaccine Use In the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i
Presentations
WHO global technical consultation: global standards and tools for influenza surveillance (8–10 March 2011)
WHO global technical consultation: global standards and tools for influenza surveillance (8–10 March 2011)
Technical and scientific products